Last update 01 Nov 2024
Shenzhou Cell Engineering Co Ltd.
Last update 01 Nov 2024
Overview
Basic Info
Introduction Shenzhou Cell Engineering Co Ltd. is an innovative biopharmaceutical and vaccine research and development company. It has established a complete set of upstream and downstream technology platforms for biopharmaceuticals and vaccines, and independently developed a rich product pipeline that covers numerous fields including malignant tumors, autoimmune diseases, genetic diseases, and disease prevention. |
Tags
Neoplasms
Infectious Diseases
Digestive System Disorders
Monoclonal antibody
Vaccine
Biosimilar
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
一项评估SCTB14用于治疗晚期恶性实体瘤患者的安全耐受性、药代动力学和抗肿瘤活性的开放、多中心、剂量递增和剂量扩展
的I/Ⅱ期临床试验
[Translation] An open, multicenter, dose-escalation and dose-expansion Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of SCTB14 in the treatment of patients with advanced malignant solid tumors
一项多中心、开放、非对照评估重组人凝血因子VIII（SCT800）在重型甲型血友病既往未经治疗患者（PUPs）中预防治疗的安全性和有效性III期研究
[Translation] A multicenter, open-label, non-controlled phase III study to evaluate the safety and efficacy of recombinant human coagulation factor VIII (SCT800) in the prevention of severe hemophilia A in previously untreated patients (PUPs)
一项评价SCTC21C在CD38+血液瘤受试者中的安全性和有效性的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety and efficacy of SCTC21C in subjects with CD38+ hematological malignancies
100 Clinical Results associated with Shenzhou Cell Engineering Co Ltd.
Login to view more data
Login to view more data
100 Deals associated with Shenzhou Cell Engineering Co Ltd.
Login to view more data
100 Translational Medicine associated with Shenzhou Cell Engineering Co Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 05 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
4
3
IND Approval
Phase 1 Clinical
2
3
Phase 2 Clinical
Phase 3 Clinical
2
2
NDA/BLA
Approved
1
3
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free